Clinical Trial Detail

NCT ID NCT03833167
Title Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

skin squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.